Quanta Therapeutics

Quanta Therapeutics company information, Employees & Contact Information

Explore related pages

Quanta Therapeutics email format Quanta Therapeutics management contacts

Related company profiles:

Novel therapeutics for conformational blockade of RAS in cancer.

Company Details

Employees
40
Founded
-
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
https://www.quantatx.com
Competitors
Allogene Therapeutics, Prelude Therapeutics, Lassen Therapeutics, Scorpion Therapeutics, Legend Biotech, Synnovation Therapeutics, Incyte, Third Arc Bio, Tempest Therapeutics, Revolution Medicines.
Looking for a particular Quanta Therapeutics employee's phone or email?

Quanta Therapeutics Questions

News

Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Yahoo Finance

Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Yahoo Finance

Quanta Therapeutics Presents Positive Phase 1 Data for - GlobeNewswire

Quanta Therapeutics Presents Positive Phase 1 Data for GlobeNewswire

Quanta Therapeutics Presents Late-Breaking Data for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025 - Yahoo Finance

Quanta Therapeutics Presents Late-Breaking Data for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025 Yahoo Finance

Quanta Announces IND Clearance by U.S. FDA for QTX3544, an - GlobeNewswire

Quanta Announces IND Clearance by U.S. FDA for QTX3544, an GlobeNewswire

Quanta Announces Dosing of First Patient in Phase 1/1b - GlobeNewswire

Quanta Announces Dosing of First Patient in Phase 1/1b GlobeNewswire

Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors - GlobeNewswire

Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors GlobeNewswire

Quanta Therapeutics Announces Oversubscribed $60 Million - GlobeNewswire

Quanta Therapeutics Announces Oversubscribed $60 Million GlobeNewswire

Companies like Quanta Therapeutics

Scorpion Therapeutics logo - Similar company to Quanta Therapeutics

Scorpion Therapeutics

35
Legend Biotech logo - Similar company to Quanta Therapeutics

Legend Biotech

2.14K
Third Arc Bio logo - Similar company to Quanta Therapeutics

Third Arc Bio

33
Lassen Therapeutics logo - Similar company to Quanta Therapeutics

Lassen Therapeutics

30
Tempest Therapeutics logo - Similar company to Quanta Therapeutics

Tempest Therapeutics

22
Incyte logo - Similar company to Quanta Therapeutics

Incyte

3.20K
Prelude Therapeutics logo - Similar company to Quanta Therapeutics

Prelude Therapeutics

135
Revolution Medicines logo - Similar company to Quanta Therapeutics

Revolution Medicines

737
Allogene Therapeutics logo - Similar company to Quanta Therapeutics

Allogene Therapeutics

222
Synnovation Therapeutics logo - Similar company to Quanta Therapeutics

Synnovation Therapeu...

48

Top Quanta Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant